GlassScriptPhysician profile
Paula Sanderlin
NPI 1871113969
$9,578.21
in general payments reported to CMS, 2019-2025
24 companies · $854 in 2025
The $854 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,695 · 2022: $2,406 · 2023: $2,440 · 2024: $2,183 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,261 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,260.83 |
| Education | $216.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,721.59 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,419.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $697.29 | 2021-2025 | |
| Ucb, INC. | $629.24 | 2021-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $601.18 | 2021-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $518.10 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $482.61 | 2021-2025 | Tremfya, Remicade, Stelara |
| Lilly USA, LLC | $468.47 | 2021-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $374.82 | 2021-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $177.37 | 2022-2023 | Orencia |
| Fresenius Kabi USA, LLC | $68.71 | 2023-2024 | Idacio |
| Organon LLC | $59.21 | 2021-2025 | Hadlima |
| Boston Scientific Corporation | $54.06 | 2023-2025 | General - Pain Management |
| Ani Pharmaceuticals, INC. | $52.21 | 2024-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $52.13 | 2024-2025 | Actemra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $37.90 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $36.48 | 2022-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $25.59 | 2024 | Arcalyst |
| Scilex Pharmaceuticals INC. | $18.45 | 2024 | |
| Arbor Pharmaceuticals, INC. | $18.19 | 2021 | |
| Horizon Therapeutics Plc | $17.41 | 2022 | |
| Genzyme Corporation | $16.90 | 2024 | |
| Pfizer INC. | $16.10 | 2021 | |
| Sobi, INC | $14.54 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Sanderlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.